Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentIntracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cellsTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Selecting the best frontline treatment in chronic myeloid leukemiaIncreased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cellsAssociation between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitroMonitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML).The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?OCT1 and imatinib transport in CML: is it clinically relevant?Chronic myeloid leukemia: First-line drug of choice.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
P2860
Q26766299-76A6DA03-BD66-47B4-9277-B43939EF25FBQ28481327-36497418-0E56-49C3-96BB-16CE55A4B7C8Q30242015-E5BCB82F-853F-414B-8607-D30A558AF4BBQ33764253-B2394284-0DAD-4315-A5FB-C2348CD83384Q33815980-85F7CE69-F046-4AC9-84A0-F3A181ED8916Q35252470-11CE0F1D-ADF0-4452-9F17-9951F8B8F8E8Q36579071-D51C40CE-E379-4305-A906-091749B88D55Q37026032-F684087E-9043-4E75-8D05-54BDEF0AA298Q37140624-035143F3-50CB-452F-B8C4-ECE24D0BECB9Q37490214-C3EA89CC-5FBE-40CF-B841-10F81C544239Q38113416-95924C8B-6210-425A-B3FD-B3CB5B026C6BQ38133575-273FA08D-5B65-4FC6-A113-41E674E23E95Q38404422-507F0CA7-E3C7-4AE0-A6C0-3D2C2454A00BQ38540022-05E57DF9-E3A2-45D3-890A-1DE194104ECEQ38697314-9FDCCBA5-D062-4EED-8B24-975BA5A682F8Q39411920-12A08B53-DA87-465C-8160-51C730FDF9D3Q50784710-A63475C5-E42F-4262-8470-2D8B338D6ADDQ54240000-6DF9136F-1619-4CDE-8384-1734753C2B65Q59236415-F0461246-BD4A-4B1D-AF41-773BA32767D9
P2860
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Chronic phase chronic myeloid ...... zed to standard-dose imatinib.
@ast
Chronic phase chronic myeloid ...... zed to standard-dose imatinib.
@en
type
label
Chronic phase chronic myeloid ...... zed to standard-dose imatinib.
@ast
Chronic phase chronic myeloid ...... zed to standard-dose imatinib.
@en
prefLabel
Chronic phase chronic myeloid ...... zed to standard-dose imatinib.
@ast
Chronic phase chronic myeloid ...... zed to standard-dose imatinib.
@en
P2093
P2860
P50
P1433
P1476
Chronic phase chronic myeloid ...... zed to standard-dose imatinib.
@en
P2093
Amity K Frede
Cassandra Slader
Daniela Cilloni
Dong Wook Kim
Jerald Radich
Lidia Mongay
Paul Manley
Phuong Dang
Richard Woodman
P2860
P304
P356
10.3324/HAEMATOL.2011.056457
P577
2011-12-29T00:00:00Z